A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome

Clinical trial NCT07558538 · RECRUITING

Trial details

NCT number: NCT07558538
Sponsor: Shanghai Zhongshan Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

ARDS (Moderate or Severe)ARDS (Acute Respiratory Distress Syndrome)

Start date: 2026-05-14
Primary completion: 2026-11-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.